GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » E10

Ionis Pharmaceuticals (Ionis Pharmaceuticals) E10 : $-0.62 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ionis Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.060. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.62 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was -23.40% per year. During the past 5 years, the average E10 Growth Rate was -47.30% per year. During the past 10 years, the average E10 Growth Rate was 5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Ionis Pharmaceuticals was 43.20% per year. The lowest was -65.80% per year. And the median was 5.75% per year.

As of today (2024-04-28), Ionis Pharmaceuticals's current stock price is $41.59. Ionis Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $-0.62. Ionis Pharmaceuticals's Shiller PE Ratio of today is .


Ionis Pharmaceuticals E10 Historical Data

The historical data trend for Ionis Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals E10 Chart

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 -0.33 -0.29 -0.41 -0.62

Ionis Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.41 -0.51 -0.56 -0.64 -0.62

Competitive Comparison of Ionis Pharmaceuticals's E10

For the Biotechnology subindustry, Ionis Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Shiller PE Ratio falls into.



Ionis Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ionis Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.06/129.4194*129.4194
=-0.060

Current CPI (Dec. 2023) = 129.4194.

Ionis Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201403 -0.270 99.695 -0.351
201406 -0.100 100.560 -0.129
201409 -0.230 100.428 -0.296
201412 0.250 99.070 0.327
201503 -0.140 99.621 -0.182
201506 0.290 100.684 0.373
201509 -0.300 100.392 -0.387
201512 -0.590 99.792 -0.765
201603 -0.520 100.470 -0.670
201606 -0.470 101.688 -0.598
201609 0.060 101.861 0.076
201612 0.210 101.863 0.267
201703 0.070 102.862 0.088
201706 -0.020 103.349 -0.025
201709 -0.020 104.136 -0.025
201712 0.020 104.011 0.025
201803 -0.010 105.290 -0.012
201806 -0.290 106.317 -0.353
201809 -0.030 106.507 -0.036
201812 2.210 105.998 2.698
201903 0.620 107.251 0.748
201906 -0.010 108.070 -0.012
201909 0.180 108.329 0.215
201912 1.280 108.420 1.528
202003 -0.280 108.902 -0.333
202006 -0.180 108.767 -0.214
202009 -0.180 109.815 -0.212
202012 -2.440 109.897 -2.873
202103 -0.640 111.754 -0.741
202106 -0.570 114.631 -0.644
202109 -0.580 115.734 -0.649
202112 1.410 117.630 1.551
202203 -0.460 121.301 -0.491
202206 -0.740 125.017 -0.766
202209 -0.330 125.227 -0.341
202212 -0.370 125.222 -0.382
202303 -0.870 127.348 -0.884
202306 -0.600 128.729 -0.603
202309 -1.030 129.860 -1.027
202312 -0.060 129.419 -0.060

Add all the adjusted EPS together and divide 10 will get our e10.


Ionis Pharmaceuticals  (NAS:IONS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Ionis Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Executives
Brian Birchler officer: EVP, Corp and Development Ops C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Patrick R. O'neil officer: SVP, Legal and General Counsel C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Onaiza Cadoret-manier officer: Chief Corp Dev and Cml Officer 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eugene Schneider officer: EVP, Chf Clinical Develop Offc C/O IONIS PHARMACEUTICALS, 2855 GAZELLE CT, CARLSBAD CA 92010
Joseph Baroldi officer: Chief Business Officer C/O IONIS PHARMACEUTICALS, INC., C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eric Swayze officer: SVP, Research 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Brett P Monia director, officer: Senior Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Richard S Geary officer: Senior Vice President 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Elizabeth L Hougen officer: SVP, Finance and CFO 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
C Frank Bennett officer: Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
B Lynne Parshall director, officer: Executive Vice President, CFO 2855 GAZELLE COURT, CARLSBAD CA 92010
Joseph Iii Klein director C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Spencer R Berthelsen director 2855 GAZELLE COURT, CARLSBAD CA 92010
Frederick T Muto director 2855 GAZELLE COURT, CARLSBAD CA 92010